1386980-37-5

Basic information

• Product Name: N-(5-(3-aminopropylcarbamoyl)-2-chlorophenyl)-2-methoxy-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carboxamide
• Synonyms: N-(5-(3-aminopropylcarbamoyl)-2-chlorophenyl)-2-methoxy-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carboxamide
• CAS NO: 1386980-37-5
• Molecular Weight: 430.851
• Mol File: 1386980-37-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: N-(5-(3-aminopropylcarbamoyl)-2-chlorophenyl)-2-methoxy-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(5-(3-aminopropylcarbamoyl)-2-chlorophenyl)-2-methoxy-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carboxamide(1386980-37-5)
• EPA Substance Registry System: N-(5-(3-aminopropylcarbamoyl)-2-chlorophenyl)-2-methoxy-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carboxamide(1386980-37-5)

Safety Data

• Hazardous Substances Data: 1386980-37-5(Hazardous Substances Data)

Upstream product

• 1386980-75-1 4-chloro-3-[(2-methoxy-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonyl)-amino]-benzoic acid 
• 109-76-2 Trimethylenediamine 
• 26664-09-5 4-amino-5-formyl-pyrimidine 
• 1386981-59-4 tert-butyl 3-(4-chloro-3-(2-methoxy-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carboxamido)benzamido)propylcarbamate 
• 1386980-73-9 2-methoxy-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid 
• 209849-69-4 2-methoxy-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid methyl ester 
• 1386979-05-0 4-chloro-3-[(2-methoxy-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonyl)-amino]-benzoic acid methyl ester 

Relevant articles and documents

Pyrido[2,3-d]pyrimidines: Discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors

DYRK1B is a kinase over-expressed in certain cancer cells (including colon, ovarian, pancreatic, etc.). Recent publications have demonstrated inhibition of DYRK1B could be an attractive target for cancer therapy. From a data-mining effort, the team has discovered analogues of pyrido[2,3-d]pyrimidines as potent enantio-selective inhibitors of DYRK1B. Cells treated with a tool compound from this series showed the same cellular effects as down regulation of DYRK1B with siRNA. Such effects are consistent with the proposed mechanism of action. Progress of the SAR study is presented.